Collection

Implications and Applications of Molecular Diagnostics in Neuro-Oncology

The field of central nervous system (CNS) oncology is rapidly changing with advances in molecular diagnostics. The therapeutic implications are being realized as it is increasingly recognized that targeted agents and immune check point inhibitors have activity in the CNS. The aim of this supplement is to summarize the state-or-the-art developments in selected tumour types with respect to molecular diagnostics and treatment options. We also welcome individual research papers specific to advancing our understanding of the therapeutic implications of genomic information for patients with CNS tumours.

Editors

  • Dr. Sunit Das

    Sunit Das is a neurosurgeon and scientist at St. Michael’s Hospital and the Hospital for Sick Kids. He is an Associate Professor and the Keenan Chair in the Department of Surgery at the University of Toronto. He currently serves as the Provincial Lead for CNS Oncology at Cancer Care Ontario. Dr. Das’s clinical practice is focused on the care of patients with benign and malignant brain tumours. His laboratory in the Arthur and Sonia Labatt Brain Tumour Centre at the Hospital for Sick Kids focuses on the molecular and genetic mechanisms that regulate tumour evolution and treatment resistance in glioblastoma.

  • Dr. Arjun Sahgal

    Dr. Arjun Sahgal is an international clinical and research leader in the field of high precision stereotactic radiation to the brain and spine for both metastases and primary tumors. He currently serves as the Chief of the Department of Radiation Oncology at the University of Toronto affiliated Sunnybrook Odette Cancer Centre. In addition, he is the director of the Sunnybrook Cancer Ablation Therapy (CAT) program which involved the installation of a MR Brachytherapy suite, MR Linac and Gamma Knife Icon technology.

Articles

Articles will be displayed here once they are published.